Generation of G51D and 3D mice reveals decreased α-synuclein tetramer-monomer ratios promote Parkinson's disease phenotypes.
Silke NuberXiaoqun ZhangThomas D McCafferyTim E MoorsMarie-Alexandre AdomWolf N HahnDylan MartinMaria EricssonArathi TripathiUlf DettmerPer SvenningssonDennis J SelkoePublished in: NPJ Parkinson's disease (2024)
Mutations in the α-Synuclein (αS) gene promote αS monomer aggregation that causes neurodegeneration in familial Parkinson's disease (fPD). However, most mouse models expressing single-mutant αS transgenes develop neuronal aggregates very slowly, and few have dopaminergic cell loss, both key characteristics of PD. To accelerate neurotoxic aggregation, we previously generated fPD αS E46K mutant mice with rationally designed triple mutations based on the α-helical repeat motif structure of αS (fPD E46K→3 K). The 3 K variant increased αS membrane association and decreased the physiological tetramer:monomer ratio, causing lipid- and vesicle-rich inclusions and robust tremor-predominant, L-DOPA responsive PD-like phenotypes. Here, we applied an analogous approach to the G51D fPD mutation and its rational amplification (G51D → 3D) to generate mutant mice. In contrast to 3 K mice, G51D and 3D mice accumulate monomers almost exclusively in the cytosol while also showing decreased αS tetramer:monomer ratios. Both 1D and 3D mutant mice gradually accumulate insoluble, higher-molecular weight αS oligomers. Round αS neuronal deposits at 12 mos immunolabel for ubiquitin and pSer129 αS, with limited proteinase K resistance. Both 1D and 3D mice undergo loss of striatal TH+ fibers and midbrain dopaminergic neurons by 12 mos and a bradykinesia responsive to L-DOPA. The 3D αS mice have decreased tetramer:monomer equilibria and recapitulate major features of PD. These fPD G51D and 3D mutant mice should be useful models to study neuronal αS-toxicity associated with bradykinetic motor phenotypes.
Keyphrases
- wild type
- high fat diet induced
- oxidative stress
- spinal cord injury
- gene expression
- parkinson disease
- computed tomography
- dna methylation
- quantum dots
- drug delivery
- mass spectrometry
- bone marrow
- mesenchymal stem cells
- deep brain stimulation
- blood brain barrier
- brain injury
- transcription factor
- skeletal muscle
- cerebral ischemia
- spinal cord
- liquid chromatography
- subarachnoid hemorrhage
- room temperature
- simultaneous determination